Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prognostic Impact of Immunohistochemical Expression of METTL-14 in Endometrial Carcinoma

NCT06861855 is registered in ClinicalTrials.gov with Assiut University as lead sponsor.

NCT NCT06861855
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06861855 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prognostic Impact of Immunohistochemical Expression of METTL-14 in Endometrial Carcinoma
Lead sponsor
Assiut University
Phase
Observational
Overall status
Not yet recruiting
Start date
September 27, 2025
Completion date
October 31, 2026
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

endometrial adenocarcinoma, endometrial cancer